Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Jessica Hall

Physician Assistant, Medical Columbia, SC Physician Assistant

NPI 1386084655 CMS profile 11179800

220 Graces Way, Columbia, SC 29229

Open in the dashboard

General payments

$21,604

1,124 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jessica Hall of Columbia, SC is reported in the CMS Open Payments database as having received $21,604 across 1,124 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $4,964 179
2024 General $3,450 182
2023 General $5,512 323
2022 General $3,483 206
2021 General $4,194 234

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jessica Hall
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Jessica Hall were reported at $4,964. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Jessica Hall Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $4,194 $156 $41–$563 $132
2022 $3,483 $185 $55–$649 $149
2023 $5,512 $199 $58–$717 $160
2024 $3,450 $206 $62–$740 $164
2025 $4,964 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $2,394 166 payments
  2. UCB, Inc. $2,270 48 payments
  3. Janssen Biotech, Inc. $1,802 87 payments
  4. Regeneron Healthcare Solutions, Inc. $1,738 67 payments
  5. Sun Pharmaceutical Industries Inc. $1,634 72 payments
  6. Mayne Pharma Inc. $1,240 166 payments
  7. Amgen Inc. $1,233 60 payments
  8. Novartis Pharmaceuticals Corporation $1,115 68 payments
  9. Incyte Corporation $921 48 payments
  10. Dermavant Sciences, Inc. $753 30 payments
  11. Other $6,504 312 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $19,589 1,111 payments
  2. Consulting Fee $1,140 1 payment
  3. Education $875 12 payments
Products named General payments · program years 2021–2025
  1. TREMFYA $2,322 83 payments
  2. Bimzelx $1,825 26 payments
  3. DUPIXENT Inflammation And Immunology $1,348 51 payments
  4. Otezla $1,211 59 payments
  5. SKYRIZI $1,170 87 payments
  6. OPZELURA $921 48 payments
  7. ILUMYA $916 47 payments
  8. DUPIXENT Immunology $909 59 payments
  9. VTAMA $781 32 payments
  10. COSENTYX $731 42 payments
  11. Other $10,153 595 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 23 drugs

Part D claims

820

Median for Physician Assistant: 241

Drug cost

$850,805

Median for Physician Assistant: $4,110

Branded share of claims

19%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Tremfya Guselkumab Brand 19 $266,118
Cosentyx Unoready Pen Secukinumab Brand 21 $253,230
Dupixent Pen Dupilumab Brand 39 $205,577
Otezla Apremilast Brand 22 $109,657
Doxycycline Hyclate Generic 87 $3,548
Clobetasol Propionate Generic 90 $2,710
Metronidazole Generic 35 $2,098
Triamcinolone Acetonide Generic 113 $1,277
Ketoconazole Generic 80 $1,124
Fluocinolone Acetonide Generic 23 $1,030

The 10 drugs with the highest cost, of 23 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 57 billing codes

Paid by Medicare

$209,258

Of which drugs: $8,731

Medicare patients

829

Average age 73

Services billed

5,902

499 women, 330 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 72%
Arthritis 45%
Ischemic heart disease 28%
Diabetes 27%
Depression 17%
Chronic kidney disease 14%
Cancer 14%
Atrial fibrillation 13%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Aminolevulinic acid hcl for topical administration, 20%, single unit dosage form (354 mg) J7308 Office 13 28 $8,682
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 27 74 $50

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 28 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
$525 39 —
SKYRIZI
$373 — —
VTAMA
$286 — —
TREMFYA
$250 19 —
OPZELURA
$241 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 28 with Patron

Records

1,124 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in South Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record